

THE CLAIMS

What is claimed is:

1. A method of treating bulimia in a patient which comprises administering to said patient in need of such treatment a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.
2. The method of claim 1, wherein the mammal is a human.
- 10 3. The method of claim 1, wherein (+) norcisapride is administered orally.
4. The method of claim 3, wherein (+) norcisapride is administered as a tablet or a capsule.
- 15 5. The method of claim 1, wherein the amount administered is from about 0.5 mg to about 500 mg.
6. The method of claim 5, wherein the amount administered is from about 1 mg to about 250 mg.
- 20 7. The method of claim 1, wherein (+) norcisapride is administered together with a pharmaceutically acceptable carrier.
8. The method of claim 3, wherein said (+) norcisapride is administered from one to four times per day.
- 25 9. The method of claim 1, wherein (+) norcisapride is administered parenterally, transdermally, rectally or sublingually.
- 30 10. A method of treating disorders mediated by vagal activity in a patient which comprises administering to said patient in need of such treatment a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

10002632 - 250000

11. The method of claim 10, wherein the mammal is a human.
12. The method of claim 10, wherein (+) norcisapride is administered orally.
- 5 13. The method of claim 12, wherein (+) norcisapride is administered as a tablet or a capsule.
14. The method of claim 10, wherein the amount administered is from about 0.5 mg to about 500 mg.
- 10 15. The method of claim 14, wherein the amount administered is from about 1 mg to about 250 mg.
- 15 16. The method of claim 10, wherein (+) norcisapride is administered together with a pharmaceutically acceptable carrier.
17. The method of claim 12, wherein said (+) norcisapride is administered from one to four times per day.
- 20 18. The method of claim 10, wherein (+) norcisapride is administered parenterally, transdermally, rectally or sublingually.
19. A method of treating irritable bowel syndrome in a patient which comprises administering to said patient in need of such treatment a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.
- 25 20. The method of claim 19, wherein the mammal is a human.
- 30 21. The method of claim 19, wherein (+) norcisapride is administered orally.
22. The method of claim 21, wherein (+) norcisapride is administered as a tablet or a capsule.

RECEIVED - DEPT OF
PATENTS - WASH. D.C.
JULY 1973

23. The method of claim 19, wherein the amount administered is from about 0.5 mg to about 500 mg.

24. The method of claim 23, wherein the amount administered is from about 1 mg to about 250 mg.

25. The method of claim 19, wherein (+) norcisapride is administered together with a pharmaceutically acceptable carrier.

10 26. The method of claim 21, wherein said (+) norcisapride is administered from one to four times per day.

15 27. The method of claim 19, wherein (+) norcisapride is administered parenterally, transdermally, rectally or sublingually.

20 28. A method of treating bradycardia or bradyarrhythmia in a patient which comprises administering to said patient in need of such treatment a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

25 29. The method of claim 28, wherein the patient is a human.

30 30. The method of claim 28, wherein (+) norcisapride is administered orally.

31. The method of claim 30, wherein (+) norcisapride is administered as a tablet or a capsule.

32. The method of claim 28, wherein the amount administered is from about 0.5 mg to about 500 mg.

30 33. The method of claim 32, wherein the amount administered is from about 1 mg to about 250 mg.

2025 RELEASE UNDER E.O. 14176

34. The method of claim 28, wherein (+) norcisapride is administered together with a pharmaceutically acceptable carrier.

35. The method of claim 30, wherein said (+) norcisapride is administered from 5 one to four times per day.

36. The method of claim 28, wherein (+) norcisapride is administered parenterally, transdermally, rectally or sublingually.

10 37. A method of treating asthma in a patient which comprises administering to said patient in need of such treatment a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

15 38. The method of claim 37, wherein the patient is a human.

39. The method of claim 37, wherein (+) norcisapride is administered orally.

20 40. The method of claim 39, wherein (+) norcisapride is administered as a tablet or a capsule.

41. The method of claim 37, wherein the amount administered is from about 0.5 mg to about 500 mg.

25 42. The method of claim 41, wherein the amount administered is from about 1 mg to about 250 mg.

43. The method of claim 37, wherein (+) norcisapride is administered together with a pharmaceutically acceptable carrier.

30 44. The method of claim 39, wherein said (+) norcisapride is administered from one to four times per day.

45. The method of claim 37, wherein (+) norcisapride is administered parenterally, transdermally, rectally or sublingually.

46. A method of treating urinary incontinence in a patient which comprises
5 administering to said patient in need of such treatment a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

47. The method of claim 46, wherein the patient is a mammal.
10

48. The method of claim 46, wherein (+) norcisapride is administered orally.

49. The method of claim 48, wherein (+) norcisapride is administered as a tablet
or a capsule.
15

50. The method of claim 46, wherein the amount administered is from about 0.5 mg to about 500 mg.
20

51. The method of claim 50, wherein the amount administered is from about 1 mg to about 250 mg.
25

52. The method of claim 46, wherein (+) norcisapride is administered together with a pharmaceutically acceptable carrier.
30

53. The method of claim 48, wherein said (+) norcisapride is administered from one to four times per day.

54. The method of claim 46, wherein (+) norcisapride is administered parenterally, transdermally, rectally or sublingually.

55. A method of treating apnea or apnea disorders in a patient which comprises
30 administering to said patient in need of such treatment a therapeutically effective amount of

SEARCHED - INDEXED - SERIALIZED - FILED

(+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

56. The method of claim 55, wherein the apnea being treated comprises central
5 apnea, deglutition apnea, obstructive apnea, sleep apnea, or sleep induced apnea.

57. The method of claim 55, wherein the patient is a human.

58. The method of claim 55, wherein (+) norcisapride is administered orally.

10 59. The method of claim 58, wherein (+) norcisapride is administered as a tablet
or a capsule.

15 60. The method of claim 55, wherein the amount administered is from about 0.5
mg to about 500 mg.

61. The method of claim 60, wherein the amount administered is from about 1
mg to about 250 mg.

20 62. The method of claim 55, wherein (+) norcisapride is administered together
with a pharmaceutically acceptable carrier.

63. The method of claim 58, wherein said (+) norcisapride is administered from
one to four times per day.

25 64. The method of claim 55, wherein (+) norcisapride is administered
parenterally, transdermally, rectally or sublingually.

30 65. A method of preventing or managing bulimia in a patient which comprises
administering to said patient in need of such prevention or management a therapeutically
effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof,
substantially free of its (-) stereoisomer.

66. A method of preventing or managing disorders mediated by vagal activity in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

5

67. A method of preventing or managing irritable bowel syndrome in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

10

68. A method of preventing or managing bradycardia or bradyarrhythmia in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

15

69. A method of preventing or managing asthma in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

20

70. A method of preventing or managing urinary incontinence in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

25

71. A method of preventing or managing apnea or apnea disorders in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.

30

Sub
B27